primary open angle glaucoma or ocular hypertension
Conditions
Interventions
Tapcom combination ophthalmic solution, QD for 12weeks
Xalacom combination eye drops, QD for 12weeks
Sponsors
Santen Pharmaceutical Co., Ltd.
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Patients who can visit the hospital according to the observation/test schedule determined in the study protocol Those with disease of which the principal investigator or subinvestigator considers requiring treatment by using a fixed dose combination drug containing a prostaglandin and a beta blocker.
Exclusion criteria
Exclusion criteria: There is risk of visual field disorder drastically progressing during the study period. Has retinal which may aggravate during the study period. Has active extraocular disease, inflammation or infection of the eye or eyelids Has corneal abnormalities or other diseases which would prohibit accurate IOP measurement by Goldmann applanation tonometer Has undergone LASIK surgery Patients who are contraindicated to beta blockers (those who with bronchial asthma or insufficiently controlled heart failure) Patients with allergy to the ingredients used in the present study Female who is pregnant, lactating, or may possibly be pregnant , wishes to become pregnant during the study period, or cannot use appropriate contraceptive method.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| IOP Change from baseline at the end of treatment | — |
Countries
Japan
Contacts
Public ContactNaomi Otsuka
Santen Pharmaceutical Co., Ltd. Japan Medical Affairs, Development Management Department, Japan Business
Outcome results
None listed